DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» SQ109
SQ109
SQ109 for the Treatment of Tuberculosis Clinical Development Status: Phase 2
Pathway Is Defined (CPTR) : • Preclinical Studies
Hydroxylation of Antitubercular Drug Candidate, SQ109, by Mycobacterial Cytochrome P450
Sequella Initiates Phase I Clinical Trial for Sq109
Mycobacterium Tuberculosis Drug Resistance
MULTI-TARGET DRUG DISCOVERY AGAINST STAPHYLOCOCCUS AUREUS and TRYPANOSOMA BRUCEI INFECTIONS by YANG WANG DISSERTATION Submitted
Global Tuberculosis Drug Development Pipeline: the Need and the Reality
Public Health Reviews
Tuberculosis Drug Information Guide, 2Nd Edition
Hydroxylation of Antitubercular Drug Candidate, SQ109, by Mycobacterial Cytochrome P450
Tuberculosis: the Drug Development Pipeline at a Glance Baptiste Villemagne, Céline Crauste, Marion Flipo, Alain Baulard, Benoit Déprez, Nicolas Willand
Mechanisms of Drug Resistance in Mycobacterium Tuberculosis: Update 2015
Dissertation Mycobacterial Arabinan Biosynthesis
The Design and Synthesis of Novel Antimicrobial Agents for Use in the Battle Against Bacterial Resistance
Synthesis and Biological Aspects of Mycolic Acids: an Important Target Against Mycobacterium Tuberculosis
Seond Line TB Drugs in Combination with a Novel Drug Candidate SQ109
Promiscuous Targets for Antitubercular Drug Discovery: the Paradigm of Dpre1 and Mmpl3
Antiinfectives Targeting Enzymes and the Proton Motive Force
Top View
Application Number
Executive Summary
Recent Progress and Challenges for Drug-Resistant Tuberculosis Treatment
Antiinfectives Targeting Enzymes and the Proton Motive Force
Chemical Classes Presenting Novel Antituberculosis Agents Currently in Different Phases of Drug Development: a 2010–2020 Review
Tuberculosis: Progress and Advances in Development of New Drugs, Treatment Regimens, and Host-Directed Therapies
Emerging Drugs for Active Tuberculosis
Handbook of Anti-Tuberculosis Agents
Pipeline Report » 2019 Tuberculosis Treatment PIPELINE REPORT 2019
SEQUELLA LEAD DRUG CANDIDATE SQ109 to BEGIN CLINICAL TESTING in PHASE 1 TRIAL a New Antibiotic for the Treatment of Pulmonary Tuberculosis, Including XDR-TB
Selected Questions and Controversies About Bedaquiline: a View from the Field
Trends in the Discovery of New Drugs for Mycobacterium Tuberculosis
Two Decades of TB Drug Discovery Efforts—What Have We Learned?
Synthesis and Biological Aspects of Mycolic Acids: an Important Target Against Mycobacterium Tuberculosis
Mycobacterial Cell Wall: a Source of Successful Targets for Old and New Drugs
SQ109 for H. Pylori
Evolution of Rifampicin Treatment for Tuberculosis T ⁎ Melanie Grobbelaara, , Gail E
Mycobacterium Tuberculosis Drug Discovery Based on Phenotypic Screening
Tuberculosis — Drugs in the 2016 40 Wall Street, New York, New York 10005, USA
Drug-Resistant Tuberculosis: a Survival Guide for Clinicians
Output-Driven Feedback System Control Platform Optimizes Combinatorial Therapy of Tuberculosis Using a Macrophage Cell Culture M
New Drugs for the Treatment of Tuberculosis
English Questionnaire